Alaa New pdf

1 Name: Alaa Alrifai and Zayed Alkatheeri Student ID: 202010405 and 202020245 Course: Marketing and Pharmacoeconomics Course ID: 0204420 Topic: Pharmaceutical Selling Skills Supervised by: Doctor Asim El Nour.

[Audio] An overview of Sotrovimab an investigational single-dose monoclonal antibody for the treatment of mild-to-moderate COVID19 in adults and pediatric patients aged 12 and older who weigh at least 40 kilograms has been developed by GlaxoSmithKline and Vir Biotechnology. Clinical trials have indicated that the drug shows positive results of direct Sars-CoV-2 viral testing and is an effective treatment for those at high risk of progression to severe COVID-19. It may help to prevent hospitalization or death. The drug was approved by the UAE’s health ministry for emergency use and was endorsed by the U-S FDA. U-A-E was the first country in the world to license and enable immediate patient use. With this approval Sotrovimab is now available for use in all patients and could help in controlling this pandemic..

3 Alaa: *sighs* Alright, send him to my office and inform him beforehand that I only have 15 minutes. Receptionist: Sure, have a good day *ends the call and turns to Zayed *. Dr. Alaa will see you now, but please keep in mind she only has 15 minutes left from her break. Zayed: Thank you so much, this is more than enough. Receptionist: Very well then, her office is just around the corner. Zayed: Thank you again, I appreciate it. * Zayed walk around the corner heading towards Samar’s office* * Zayed knocks on the door* Alaa: Come in *eats food* Zayed: Good morning Dr. Samar, I am really sorry for cutting your break short but this meeting couldn’t be postponed. Alaa: It’s okay, I was told that this meeting is urgent. You had me really curious though, please have a seat Mr . . . . Zayed: Zayed Alkatheeri, a medical representative for GSK short for GlaxoSmithKline . . . Alaa: Oh, isn’t that the company that manufactured Panadol? Zayed: Yes, that’s right. Alaa: Impressive . . . So what is so urgent it couldn’t wait? Zayed: Alright, so allow me to briefly introduce the company I am representing; GSK began in 1715 with the opening of an apothecary shop in London, our story has always focused on innovation. From a selection of individual entrepreneurs to a global company of around 100,000 employees, we’ve developed a variety of medicines and healthcare products that form the foundations of today’s GSK. Through 1715 – 1891: The early history of GSK shows how a range of entrepreneurs built the foundations of the GSK we know today. Throughout 1892 – 1918 In this period, our legacy companies expanded globally, developing and selling new products worldwide. Past 1892 – 1918 in this period, our legacy companies expanded globally,.

[Audio] G-S-K is a leader in the healthcare industry continually innovating over the last seven decades to advance the standards of care and improve people's lives. Most recently G-S-K has developed and launched Sotrovimab an investigational single-dose monoclonal antibody for the treatment of mild-to-moderate COVID-19 which has been approved by the UAE's health ministry and U-S FDA. When a patient tests positive for the virus the medical team follows a standard protocol to ensure their safety including measuring vital signs recording a medical history and performing a chest X-ray. Those without chronic conditions are usually instructed to isolate at home and take a course of vitamins and panadol while those with chronic conditions receive an additional antiviral drug. G-S-K is proud to be part of the fight against the pandemic and make a difference in people's lives with innovative new products..

[Audio] Sotrovimab an investigational monoclonal antibodies drug developed by G-S-K and Vir Biotechnology is designed to neutralize the Sars-Cov-2 virus by surrounding its spike protein and preventing it from interacting with the ACE-2 receptor on the cell membrane and entering the cell. On 26th of May 2021 the U-S FDA issued an emergency use authorization for sotrovimab. Results of clinical trials have indicated that sotrovimab has a higher Absolute Risk Reduction of 7.3% and a higher Relative Risk Reduction of 96% than the drugs Bamlanivimab plus Etesivimab and Casirivimab plus Imdevimab. In addition the Number Needed To Treat for Sotrovimab is only 14 patients which is significantly lower than the 20 or 20 needed to treat with the other drugs. This means doctors can prevent one death by treating 14 patients with sotrovimab as opposed to treating 20 or more patients with the other drugs..

[Audio] Sotrovimab is an investigational single-dose monoclonal antibody approved by the UAE's health ministry and the U-S FDA for the treatment of mild-to-moderate COVID-19. It is indicated for most adults and children aged 12 years or older who weigh at least 40 kilograms and is considered safe for pregnant women category B2. However it is contraindicated in pregnant women and those with certain conditions and treatments that make them more prone to infection. It should be administered within 7 days of symptom onset and may be a promising treatment for those with mild-to-moderate COVID-19 symptoms..

[Audio] Sotrovimab is still an option for patients who have had radiotherapy in the last 6 months however clinicians and their patients must understand the potential unexpected risks associated with the drug including allergic reactions. The drug is F-D-A approved registered with the Ministry of Health and available to be prescribed. The pricing for the treatment is 2 100 dollars or 7 707 Dirhams per single vial which may seem expensive but may be worth the cost due to its efficacy and ability to reduce mortality. According to the Ministry of Health and Prevention Sotrovimab proved 100 percent successful in preventing deaths and 99 percent effective in stopping admissions to intensive care in more than 6000 patients over a two-week period in early July in the UAE. Overall this drug is being hailed as a game-changer in the treatment of the coronavirus with almost 97 per cent of recipients fully recovering within 14 days in line with the trial’s previous findings..

[Audio] Dr Anwar Salam chief medical officer at Seha the Abu Dhabi health services company has commended the swift adoption of Sotrovimab an investigational single-dose monoclonal antibody for the treatment of mild-to-moderate COVID-19 approved by the UAE's health ministry and the U-S FDA. Sotrovimab has demonstrated effectiveness in combating the Omicron Variant of COVID-19 prompting the F-D-A to withdraw approval of other monoclonal antibodies to address this strain. The cost per hospitalization associated with Sotrovimab is the highest at $91000 but the cost per quality-adjusted life year is $69000 much lower than the ICER's threshold of $100000. Resources such as the COVID-19 Real-Time Learning Network and G-S-K and Vir Biotechnology have enabled Sotrovimab to gain authorization and be used to support those in need. Accounts from Sotrovimab recipients have corroborated positive results in a short period of time as a result of this treatment..

[Audio] Recent studies indicate that Sotrovimab an investigational single-dose monoclonal antibody for the treatment of mild-to-moderate COVID-19 may be able to reduce hospital stays and eliminate the need for oxygen for some patients significantly reducing the costs associated with hospitalization for COVID-19. An independent cost-effectiveness organization I-C-E-R has determined that Sotrovimab is cost effective demonstrating that it can provide a valuable treatment option at a reasonable cost..